Obesity

  • Antiobesity drug therapy
    Taher Modarressi, MD
    Cleveland Clinic Journal of Medicine December 2021, 88 (12) 657; DOI: https://doi.org/10.3949/ccjm.88c.12001
  • Physician resistance to obesity pharmacotherapy
    Vania Modesto-Lowe, MD, Allison Wick, BS and Michael Dang, BS, MD
    Cleveland Clinic Journal of Medicine December 2021, 88 (12) 658; DOI: https://doi.org/10.3949/ccjm.88c.12003
  • In Reply: Antiobesity drug therapy
    Yael Mauer, MD, MPH, Marcie Parker, PharmD, BCACP and Sangeeta Kashyap, MD
    Cleveland Clinic Journal of Medicine December 2021, 88 (12) 657-658; DOI: https://doi.org/10.3949/ccjm.88c.12002
  • In Reply: Physician resistance to obesity pharmacotherapy
    Yael Mauer, MD, MPH, Marcie Parker, PharmD, BCACP and Sangeeta Kashyap, MD
    Cleveland Clinic Journal of Medicine December 2021, 88 (12) 658-659; DOI: https://doi.org/10.3949/ccjm.88c.12004
  • Antiobesity drug therapy: An individualized and comprehensive approach
    Yael Mauer, MD, MPH, Marcie Parker, PharmD, BCACP and Sangeeta R. Kashyap, MD
    Cleveland Clinic Journal of Medicine August 2021, 88 (8) 440-448; DOI: https://doi.org/10.3949/ccjm.88a.20080

    As part of a comprehensive plan, these drugs can provide lasting obesity control and additional health benefits, including decreased cardiovascular risk.

  • The obesity paradox in heart failure: What is the role of cardiorespiratory fitness?
    Asad Khan, MD, Erik H. Van Iterson, PhD and Luke J. Laffin, MD
    Cleveland Clinic Journal of Medicine August 2021, 88 (8) 449-458; DOI: https://doi.org/10.3949/ccjm.88a.20098

    What should these patients be advised about weight management and about cardiorespiratory fitness, a major factor influencing the paradox?

  • Promoting physical activity in older women to maximize health
    CME article
    Augustine Chavez, MD, Robert Scales, PhD and Juliana M. Kling, MD, MPH
    Cleveland Clinic Journal of Medicine July 2021, 88 (7) 405-415; DOI: https://doi.org/10.3949/ccjm.88a.20170

    The optimal type, intensity, and level required to achieve specific health outcomes depend on the disease the patient and clinician are trying to prevent or manage.

  • Medical complications of bulimia nervosa
    CME article
    Allison Nitsch, MD, Heather Dlugosz, MD, Dennis Gibson, MD and Philip S. Mehler, MD, FACP, FAED
    Cleveland Clinic Journal of Medicine June 2021, 88 (6) 333-343; DOI: https://doi.org/10.3949/ccjm.88a.20168

    Complications can affect all body systems, but especially the renal and electrolyte systems.

  • Point-of-care ultrasonography for the hospitalist
    Point-of-care ultrasonography for the hospitalist
    Guramrinder Singh Thind, MD, Steven Fox, MD, Mohit Gupta, MD, Praveen Chahar, MD, Robert Jones, DO, FACEP and Siddharth Dugar, MD
    Cleveland Clinic Journal of Medicine June 2021, 88 (6) 345-359; DOI: https://doi.org/10.3949/ccjm.88a.20141

    POCUS has emerged as a vital tool in various disciplines of medicine.

  • The role of SGLT-2 inhibitors in managing type 2 diabetes
    Yumiko Tsushima, MD, M. Cecilia Lansang, MD, MPH and Vinni Makin, MBBS, MD, FACE
    Cleveland Clinic Journal of Medicine January 2021, 88 (1) 47-58; DOI: https://doi.org/10.3949/ccjm.88a.20088

    These drugs improve glycemic control and offer cardiovascular and metabolic benefits.

Pages